Chargement de la fiche…
rhumatologie
Dr Charles Zarnitsky
Salivary Gland Disorders and Functions · Rheumatoid Arthritis Research and Therapies · Systemic Lupus Erythematosus Research
0Publications
0Citations
0Citations de la publi la +
Côté patient
Avant votre rendez-vous avec le Dr Charles Zarnitsky
Choisissez votre pathologie pour une explication en langage simple.
Parcourir toutes les pathologies →Des applications évaluées par MonRhumato, sélectionnées pour les patients.
MapathoPlateforme communautaire maladies chroniques + annuaire pair-validé
GustaveAgent IA souverain pour information patient sourcée
Remedee LabsBracelet stimulateur d'endorphines pour douleur chroniquePourquoi consulter Dr Charles Zarnitsky
- Auteur de référence en rhumatologie
- Référence presse grand public
Tout est calculé à partir des sources publiques (RPPS, PubMed, OpenAlex, OpenStreetMap…) — aucun classement éditorial.
Parcours
2011–2021
Groupe Hospitalier du Havre
2019–2020
Université Le Havre Normandie
2013–2016
Université Le Havre Normandie
2014
Université Paris-Sud
2014
Université de Bretagne Occidentale
2014
Centre Hospitalier Universitaire de Nantes
Rayonnement scientifique
0
h-index
0
i10
0
citations
Le h-index mesure la productivité scientifique : ce médecin a publié 19 articles cités au moins 19fois par d'autres chercheurs. Plus c'est élevé, plus son travail influence la communauté médicale.
Dernières publications
Publications les plus citées
312 citationsTreatment of primary Sjögren syndrome with rituximab: a randomized trial2014 · Annals of internal medicinePubMed ↗233 citationsEffects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial2014 · JAMAPubMed ↗165 citationsEfficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry2013 · Annals of the rheumatic diseasesPubMed ↗
Diplômes & qualifications
DES
Rhumatologie (SM) — Diplôme d'Études Spécialisées
CES
CES Rhumatologie · DE Docteur en médecine — Capacité / Certificat d'Études Spéciales
Lieu d'exercice
localisation non renseignée
Domaines d'expertise
Salivary Gland Disorders and FunctionsRheumatoid Arthritis Research and TherapiesSystemic Lupus Erythematosus ResearchMultiple Myeloma Research and TreatmentsSpondyloarthritis Studies and Treatments
Bibliométrie (OpenAlex)
Profil ↗0
travaux
0
h-index
0
i10-index
0
citations
Salivary Gland Disorders and FunctionsRheumatoid Arthritis Research and TherapiesSystemic Lupus Erythematosus ResearchMultiple Myeloma Research and TreatmentsSpondyloarthritis Studies and Treatments
Transversal
102021Clinical laboratory
PubMed ↗IgG1 Subclass Restriction and Biochemical Peculiarities of Monoclonal Immunoglobulins in Scleromyxedema
2020La Revue de medecine interne
PubMed ↗Effet indésirable rare d’un anti-IL-1RA
2020Blood
PubMed ↗Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema
2019American journal of hematology
PubMed ↗Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot study
2019British journal of haematology
PubMed ↗Daratumumab and dexamethasone is safe and effective for triple refractory myeloma patients: final results of the IFM 2014-04 (Etoile du Nord) trial
2015Joint bone spine
PubMed ↗Validation of the 2010-ACR/EULAR -classification criteria using newly EULAR-defined erosion for rheumatoid arthritis on the very early arthritis community-based (VErA) cohort
2012Joint bone spine
PubMed ↗Analgesic effect of sacroplasty in osteoporotic sacral fractures: a study of six cases
2010Arthritis care & research
PubMed ↗Serum IgA rheumatoid factor and pyridinoline in very early arthritis as predictors of erosion(s) at two years: a simple model of prediction from a conservatively treated community-based inception cohort
1998Revue du rhumatisme (English ed.)
PubMed ↗Isolated polyarthritis followed by systemic polyangiitis with antineutrophil cytoplasmic antibody
1997Revue du rhumatisme (English ed.)
PubMed ↗Thromboangiitis obliterans with arthralgia, diarrhea and nodules as the first symptoms
Sjögren
82021Annals of the rheumatic diseases
PubMed ↗Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial
2017Arthritis care & research
PubMed ↗Severe Health-Related Quality of Life Impairment in Active Primary Sjögren's Syndrome and Patient-Reported Outcomes: Data From a Large Therapeutic Trial
2015Rheumatology (Oxford, England)
PubMed ↗Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy
2015PloS one
PubMed ↗Which and How Many Patients Should Be Included in Randomised Controlled Trials to Demonstrate the Efficacy of Biologics in Primary Sjögren's Syndrome?
2014Annals of internal medicine
PubMed ↗Treatment of primary Sjögren syndrome with rituximab: a randomized trial
2014JAMA
PubMed ↗Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial
2013Arthritis care & research
PubMed ↗European League Against Rheumatism Sjögren's Syndrome Disease Activity Index and European League Against Rheumatism Sjögren's Syndrome Patient-Reported Index: a complete picture of primary Sjögren's syndrome patients
2013Annals of the rheumatic diseases
PubMed ↗Efficacy of rituximab in systemic manifestations of primary Sjogren's syndrome: results in 78 patients of the AutoImmune and Rituximab registry
Anti-TNF
42016JAMA
PubMed ↗Non-TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial
2013Joint bone spine
PubMed ↗Efficacy of anti-TNF in patients with spondyloarthritis in absence of any imaging sign
2009Rheumatology (Oxford, England)
PubMed ↗Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial
2008Annals of the rheumatic diseases
PubMed ↗Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis
csDMARDs
32020La Revue de medecine interne
PubMed ↗[Drug-induced Sweet's syndrome related to hydroxychloroquine: About 2 cases]
2014JAMA
PubMed ↗Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren syndrome: the JOQUER randomized clinical trial
2009Rheumatology (Oxford, England)
PubMed ↗Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial
Biothérapies non-anti-TNF
2Corticothérapie
12015Haematologica
PubMed ↗Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide
Épidémiologie & registres
12021European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
PubMed ↗Microbiological diagnosis of suspected vertebral osteomyelitis with a focus on the yield of percutaneous needle biopsy: a 10-year cohort study
Pharmacovigilance
12023Haematologica
PubMed ↗Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
Vascularites
12021La Revue de medecine interne
PubMed ↗[ANCA vasculitis preceded by isolated joint manifestations. Report of two cases and literature review]
Vraie vie / RWE
12023Haematologica
PubMed ↗Real-world study of the efficacy and safety of belantamab mafodotin (GSK2857916) in relapsed or refractory multiple myeloma based on data from the nominative ATU in France: the IFM 2020-04 study
Publications HAL
82025Article
Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial
The Lancet
2024Article
Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort
Rheumatology
2022Congrès
Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study
64th ASH Annual Meeting and Exposition
2021Article
IgG1 Subclass Restriction and Biochemical Peculiarities of Monoclonal Immunoglobulins in Scleromyxedema
Clinical Laboratory
2021Article
Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial
Annals of the Rheumatic Diseases
2020Article
Microbiological diagnosis of suspected vertebral osteomyelitis with a focus on the yield of percutaneous needle biopsy: a 10-year cohort study
European Journal of Clinical Microbiology and Infectious Diseases
2020Article
Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema.
Blood
2019Article
Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials
The Lancet Rheumatology
Données issues de l'Annuaire Santé (ANS) — Licence Ouverte 2.0. Enrichissements à partir de sources publiques. Vous êtes le praticien référencé ? Faites corriger ou retirer votre fiche : demande de rectification ou de retrait.